
The Centers for Disease Control and Prevention endorsed updated recommendations expressing a clinical preference for individuals to receive an mRNA COVID-19 vaccine over Johnson & Johnson’s COVID-19 vaccine, as proposed by the agency’s Advisory Committee on Immunization Practices.